Article

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775

2025-12-02

Abstract excerpt

Covalent targeting of EGFR cysteine 797 by osimertinib is one of the most successful breakthroughs in targeted therapy, fundamentally transforming the treatment landscape for non-small cell lung cancer (NSCLC) patients. However, resistance driven by mutation of C797 remains a major clinical challenge. Developing novel covalent strategies beyond C797 targeting presents a compelling opportunity for next-generation E...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4409640d-1e63-541f-bb79-13ceba44cd2f
DOI: 10.64898/2025.11.28.691243

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775DOI 10.64898/2025.11.28.691243Read

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.Semantic proximity Read

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.Semantic proximity Read

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.Semantic proximity Read

Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read

Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance.Semantic proximity Read

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.Semantic proximity Read

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLCSemantic proximity Read

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds.Semantic proximity Read

Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation.Semantic proximity Read

Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor InhibitorsSemantic proximity Read

Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors.Semantic proximity Read

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.Semantic proximity Read